COMPARISON OF INTRAVITREAL BEVACIZUMAB AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY

##plugins.themes.academic_pro.article.sidebar##

Published Nov 15, 2022
Download
PDF
Statistic

Downloads

Download data is not yet available.
Vol. 5 No. 06 (2022): International Journal of Medical Science in Clinical Research and Review

##plugins.themes.academic_pro.article.main##

Arul Prasath
Babitha Rexlin
Dr.MGR medical university
Rini Evangeline
Dr.MGR medical university
Ramesh kumar
Dr.MGR medical university

Abstract

ABSTRACT


Background


ROP is a Vaso proliferative retinal condition that affects preterm babies. Early identification and treatment of ROP is highly beneficial in protecting a newborn's vision. ROP was initially treated with cryotherapy. Laser photocoagulation later became the conventional therapy for ROP over time. Bevacizumab, a recombinant monoclonal antibody against VEGFR, is currently used to treat ROP. In this study, we investigated the effectiveness of bevacizumab against laser photocoagulation for treating type 1 ROP


Method


This retrospective study was conducted in the department of neonatology, Kanyakumari government medical college. Thirty-six neonates who met the criteria for Type 1 ROP and were treated with either PRP or bevacizumab were followed up till 90 weeks postmenstrual age. The primary outcome markers such as ROP recurrences needing re-treatment and significant complications were documented for each treatment group.


Result


A total of 72 eyes from 36 premature newborns with type 1 ROP were treated. Laser photocoagulation was performed in 30 eyes in 15 cases (41.7%), while IVB injection was performed in 42 eyes in 21 cases (41.7%). (58.3%). A total of 6 eyes had a recurrence, and the recurrence rate was 6.7% for PRP and 9.5 % for IVB. All cases with recurrence had Zone 2 ROP.


Conclusion


Both PRP and IVB are effective treatment options for treating type 1 ROP in both zones 1 and 2. Future RCT studies including larger sample numbers and longer follow-up periods are recommended.


 


Keywords: ROP-Retinopathy of prematurity, PRP-pan retinal photocoagulation, IVB-intravitreal bevacizumab.

##plugins.themes.academic_pro.article.details##

How to Cite
Prasath, A., Rexlin, B., Evangeline, R., & kumar, R. (2022). COMPARISON OF INTRAVITREAL BEVACIZUMAB AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY. International Journal of Medical Science in Clinical Research and Review, 5(06), Page: 1069–1073. Retrieved from http://ijmscrr.in/index.php/ijmscrr/article/view/396

References

    REFERENCES
    1. Kang HG, Choi EY, Byeon SH, Kim SS, et al. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Korean J Ophthalmol. 2018;32(6):451-458.
    2. Shukla R, Murthy GVS, Gilbert C, Vidyadhar B, et al. Operational guidelines for ROP in India: A summary. Indian J Ophthalmol. 2020;68 (Suppl 1): S108-S114.
    3. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012; 367: 2515–2526.
    4. Villegas Becerril E, Gonzalez Fernandez R, Fernandez Molina F, Gallardo Galera JM. Growth factor levels and ROP. Ophthalmol. 2005; 112: 2238.
    5. Freitas AM, Mörschbächer R, Thorell MR, Rhoden EL. Incidence and risk factors for retinopathy of prematurity: a retrospective cohort study. Int J Retina Vitreous. 2018;4(1).
    6. Good WV. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-48.
    7. Mechoulam H, Pierce EA. Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am J Pharmacogenomics. 2003;3(4):261-77.
    8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114: 855–859.
    9. Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35: 675–680.
    10. Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130(6):801-2.
    11. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, et al. Reactivation of Retinopathy of Prematurity After Bevacizumab Injection. Arch Ophthalmol. 2012;130(8):1000–1006.
    12. Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, et al. efficacy of intravitreal bevacizumab for Zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6): e417-20.
    13. Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Dastjani Farahani A, et al. Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. Ophthalmol Retina. 2018;2(9):942-948.
    14. Kabataş EU, Kurtul BE, Altıaylık Özer P, Kabataş N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054–8.
    15. W.C. Wu, H.K. Kuo, P.T. Yeh, C.M. Yang, et al. Chen. An updated study of the use of bevacizumab in the treatment of patients with pre-threshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155(1):150-158.e1.
    16. Walker K, Holland AJA, Winlaw D, Sherwood M, et al. Neurodevelopmental outcomes and surgery in neonates. J Paediatr Child Health. 2006;42(12):749–51.
    17. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–15.
    18. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008–15.
    19. Chandra P, Chawla D, Chairperson Ashok, Deorari K, et al. Clinical practice guidelines screening and management of retinopathy of prematurity. Nnfi.org. 2020.